- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02988843
Study of Brentuximab Vedotin And Bevacizumab In Refractory CD-30 Positive Germ Cell Tumors
Phase II Study of Brentuximab Vedotin and Bevacizumab in Men With Refractory CD-30 Positive Germ Cell Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55455
- University of Minnesota
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male, ≥ 18 years of age
- Diagnosis of CD-30 positive germ cell tumor. CD30 expression will be tested by immunohistochemistry (IHC) in archival or fresh tumor tissue as is routinely done for diagnosis.
- Disease progression on imaging or tumor marker progression (clinical significance of tumor marker progression to be decided per the discretion of treating physician) after at least 2 lines of platinum-based chemotherapies unless patient is ineligible for further platinum based chemotherapy or refuses 2nd line platinum based chemotherapy due to toxicity. For primary mediastinal germ cell tumors, failure of first-line chemotherapy will be accepted. Prior high dose chemotherapy with hematopoietic stem cell rescue is allowed. Prior treatment with bevacizumab is allowed.
- At least 3 weeks should have elapsed since the last treatment (e.g. chemotherapy, targeted small molecule therapy, immunotherapy or radiation) and must have recovered to grade 1 or better from the acute effects of prior therapy.
- Presence of measurable disease according to RECIST 1.1
- ECOG performance status 0 or 1
Adequate marrow and organ function within 28 days prior to study registration as defined below:
- Leukocytes > 3,000/µL
- ANC > 1500/µL
- Hemoglobin ≥ 9 g/dL, Note: Blood transfusion will be allowed for patients with hemoglobin < 9 g/dl and G-CSF is allowed for neutropenic patients at time of enrollment.
- Platelets > 100,000/mm3
- Creatinine: ≤3mg/dl OR if serum creatinine > 3 mg/dl, estimated GFR >30 mL/min/1.73m2
- INR: <1.5 x institutional upper limit of normal OR < 3 if on warfarin or other anticoagulants. There should be no evidence of active bleeding while on anticoagulants.
- Total bilirubin: ≤ 2 x institutional upper limit of normal (ULN)
- SGOT (AST) or SGPT (ALT): < 3 x institutional upper limit of normal (< 5 x ULN if liver metastases present)
- Proteinuria: If patient has proteinuria, it should be <2+ (< 100 mg/dl or per institutional guidelines). If proteinuria is 2+ or greater (≥ 100 mg/dl per institutional guidelines), patients should undergo a 24- hour urine collection and 24 hour urinary protein should be less than < 2 grams.
- Sexually active men with partners of women of childbearing potential must agree to practice effective methods of contraception during the study and for 6 months after the last treatment
- Provide voluntary written consent and HIPAA authorization for release of personal health information, approved by an Institutional Review Board/Independent Ethics Committee (IRB/IEC)
Exclusion Criteria:
- Prior treatment with Brentuximab Vedotin.
- Known active brain metastases and or carcinomatous meningitis. Subjects with previously treated brain metastases may participate provided brain metastases are stable (without evidence of progression by imaging for at least four weeks prior to the first dose of trial treatment and any neurologic symptoms have returned to baseline), have no evidence of new or enlarging brain metastases, and are not using steroids for at least 7 days prior to study registration. This exception does not include carcinomatous meningitis, which is excluded regardless of clinical stability.
- History of blood clots, pulmonary embolism, or deep vein thrombosis in previous 6 months unless controlled by anticoagulant treatment
- Known history of HIV
- Known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected)
- Received a live vaccine within 1 week prior to the first dose of study treatment
- Has active autoimmune disease that required systemic treatment with use of disease modifying agents, corticosteroids or immunosuppressive drugs
- Any clinically significant active infection that requires systemic treatment at the time of enrollment.
- Known allergy to bevacizumab or brentuximab vedotin or any of its excipients
- Patients who have congestive heart failure (NYHA Class III or IV), unstable angina, sustained ventricular tachycardia, ventricular fibrillation, clinically significant bradycardia, advanced heart block or a history of acute myocardial infarction (MI) within 6 months of study registration
- History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess in previous 6 months
- Prior major surgery within the previous 28 days of study registration and/or presence of any non-healing wound, fracture, or ulcer.
- Use of an investigational agent within the previous 28 days of study registration.
- Poorly controlled hypertension [defined as systolic blood pressure (SBP) of ≥150 mmHg and/or diastolic blood pressure (DBP) of ≥ 90mmHg]. Note: Initiation or adjustment of antihypertensive medication(s) is permitted prior to study registration
- Arterial thromboembolic events, including transient ischemic attack (TIA), cerebrovascular accident (CVA), unstable angina, or MI within 6 months of study registration
- History of posterior reversible encephalopathy syndrome
- Other malignancies unless the patient is considered to be disease-free and has completed therapy for the malignancy > than 6 months prior to study entry
- Any serious and/or unstable pre-existing medical, psychiatric, or other condition that could interfere with subject's safety, provision of informed consent, or compliance to study procedures
- Concurrent use of rifampin or ketoconazole
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Brentuximab Vedotin & Bevacizumab
|
Dose level 1: 1.8 mg/kg every 21 days (up to 180 mg) Dose level -1 :1.2 mg/kg every 21 days ( up to 120 mg)
Other Names:
15 mg/kg every 21 days
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Disease Response Rate as Defined by the RECIST 1.1 Criteria, Integrated With Tumor Marker Response.
Time Frame: 1 year
|
Changes in the largest diameter (unidimensional measurement) of the tumor lesions and the shortest diameter in the case of malignant lymph nodes are used in the RECIST criteria. In addition to CT scan to assess for disease evaluation, whole body bone scans will be done for patients with known or suspected bone metastases to assess for bone lesions. |
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants Experiencing Progression Free Survival
Time Frame: 2 years
|
Incidence of Progression-free survival - Number of patients who were alive and did not have disease progression
|
2 years
|
Number of Participants Who Were Alive at 2 Years - Overall Survival
Time Frame: 2 years
|
Number of participants who were alive at 2 years (Overall survival)
|
2 years
|
Number of Participants Experiencing Adverse Events (AE) and Severe Adverse Events (SAE)
Time Frame: 2 Years
|
Safety/ toxicity of brentuximab vedotin, measured by incidence of AEs/SAEs
|
2 Years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Shilpa Gupta, University of Minnesota
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2015LS190
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Germ Cell Tumor
-
Nabil AdraRecruitingOvarian Germ Cell Tumor | Germ Cell Tumor | Non-seminomatous Germ Cell TumorUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedExtragonadal Germ Cell Tumor | Childhood Germ Cell TumorCanada, United States, Australia, Puerto Rico
-
Jennifer KingExelixisRecruitingOvarian Germ Cell Tumor | Seminoma | Germ Cell Tumor | Non-seminomatous Germ Cell TumorUnited States
-
Memorial Sloan Kettering Cancer CenterAstraZenecaActive, not recruitingNonseminomatous Germ Cell Tumor | Seminoma | Germ Cell Tumor | Dysgerminoma | Pineal Germ Cell Tumor | Germinomatous Germ Cell TumorUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedTesticular Germ Cell Tumor | Ovarian Cancer | Extragonadal Germ Cell Tumor | Childhood Germ Cell Tumor
-
UNICANCERTerminatedTesticular Germ Cell Tumor | Ovarian Cancer | Extragonadal Germ Cell Tumor | Childhood Germ Cell TumorFrance
-
N.N. Petrov National Medical Research Center of...RecruitingTesticular Germ Cell TumorRussian Federation
-
Royal Marsden NHS Foundation TrustUniversity College London (UCL) Cancer InstituteUnknownTesticular Germ Cell TumorUnited Kingdom
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Teratoma | Stage II Malignant Testicular Germ Cell Tumor | Stage III Malignant Testicular Germ Cell Tumor | Childhood Embryonal Tumor | Childhood Extracranial Germ Cell Tumor | Childhood Extragonadal Germ Cell Tumor | Childhood Malignant Ovarian Germ Cell Tumor | Childhood Malignant Testicular... and other conditionsUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Massachusetts General HospitalDana-Farber Cancer Institute; National Institutes of Health (NIH)UnknownGerm Cell Tumor | Central Nervous System Germ Cell TumorUnited States
Clinical Trials on Brentuximab Vedotin
-
Seagen Inc.Millennium Pharmaceuticals, Inc.CompletedLymphoma, Non-Hodgkin | Lymphoma, Large-Cell, Anaplastic | Disease, HodgkinUnited States, France
-
Seagen Inc.TerminatedSystemic Lupus ErythematosusUnited States
-
University Hospital, CaenRecruiting
-
Washington University School of MedicineSeagen Inc.CompletedMyelodysplastic Syndromes | Leukemia, Acute Myeloid | Leukemia, Lymphoblastic,AcuteUnited States
-
Seagen Inc.Millennium Pharmaceuticals, Inc.CompletedLymphoma, Non-Hodgkin | Lymphoma, Large-Cell, Anaplastic | Disease, HodgkinUnited States, Germany
-
Fondazione Italiana Linfomi ONLUSCompletedRelapsed/Refractory Hodgkin's LymphomaItaly
-
Seagen Inc.CompletedLymphoma, Non-Hodgkin | Lymphoma, Large-Cell, Anaplastic | Disease, HodgkinUnited States
-
Seagen Inc.Millennium Pharmaceuticals, Inc.No longer availableLymphoma, Non-Hodgkin | Lymphoma, T-Cell, Cutaneous | Lymphoma, Large-Cell, Anaplastic | Disease, HodgkinUnited States, United Kingdom, Belgium, Serbia, Australia, Bulgaria, France, Germany, Hungary, Italy, Poland, Romania, Russian Federation, Spain, Switzerland
-
Seoul National University HospitalSeoul National University Bundang Hospital; SMG-SNU Boramae Medical CenterCompletedRelapsed or Refractory EBV-and CD30-positive LymphomasKorea, Republic of
-
Samsung Medical CenterMillennium Pharmaceuticals, Inc.CompletedNon-Hodgkin LymphomaKorea, Republic of